Compare LASE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | TCRX |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.3M | 49.4M |
| IPO Year | 2021 | 2021 |
| Metric | LASE | TCRX |
|---|---|---|
| Price | $1.29 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.8M | 470.5K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | $721,185.00 | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.38 | $0.72 |
| 52 Week High | $6.77 | $2.57 |
| Indicator | LASE | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 44.78 |
| Support Level | $0.83 | $0.73 |
| Resistance Level | $1.30 | $0.80 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 55.78 | 50.25 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasive blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, machine manufacturing, nuclear maintenance and decommissioning, and surface coating. Geographically, the company generates almost all of its revenue from the domestic market.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.